| Bioactivity | MT-802 is a potent BTK degrader based on Cereblon ligand, with a DC50 of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL)[1]. | ||||||||||||
| Target | DC50: 1 nM (BTK). | ||||||||||||
| Invitro | MT-802 degrades BTK with a DC50 of 9.1 nM with maximal degradation being observed by 250 nM[1]. | ||||||||||||
| Name | MT-802 | ||||||||||||
| CAS | 2231744-29-7 | ||||||||||||
| Formula | C41H41N9O8 | ||||||||||||
| Molar Mass | 787.82 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Buhimschi AD, et al. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Biochemistry. 2018 Jul 3;57(26):3564-3575. |